• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EYEFI Expanding to the United States

    6/23/21 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care
    Get the next $BSX alert in real time by email

    TORONTO, ON / ACCESSWIRE / June 23, 2021 / EYEFI Group Technologies Inc. (CSE:EGTI)(OTC:EGTTF) ("the "Company") is pleased to announce the appointment of Dr Ian Meredith AM to EYEFI's US based advisory board to assist with expansion activities in the United States. Dr Meredith is Executive Vice President and global Chief Medical Officer, at Boston Scientific Corporation (NYSE:BSX) (a US$60B Fortune 500 device company headquartered in the United States). In this role, he is responsible for leading clinical science and medical affairs across Boston Scientific and providing global leadership of the company's clinical trial strategy.

    EYEFI's geospatial technology ‘SPARC' is a registered patent in 7 countries including Canada and the United States. The technology includes a set of proprietary algorithms that can be installed on any camera or sensor and used to determine the location of any object being viewed or pointed at by the device. The solution does not use GPS, satellite or the internet and it is totally covert and undetectable when in use. The algorithms also have several proprietary modules, for instance an image that has been captured using SPARC can be shared or integrated into 3rd party applications to conduct a reverse look up on any pixel to pull location data, plus any other dataset on the internet that is relevant to that location at that time.

    There are a broad range of use cases for the SPARC technology for use in drones, autonomous vehicles, military, and in medical devices. There is a growing demand for medical devices to leverage spatial and 3D data, such as Google Glass (owned by Google), Tesla owned by Elon Musk, and NeuraLink; another company backed by Elon Musk that is developing devices to interface with the human brain.

    Dr Meredith has joined EYEFI's US based advisory board to assist the Company with strategic introductions to potential new US based customers and channel partners. Several key targets have already been identified in addition to those mentioned above.

    Dr Meredith's remuneration will include 20,000 options with an exercise price of $.82 with 12-month expiry. An additional 100,000 options will be issued with an exercise price of $1.30, with vesting conditions (remain as consultant and provide a minimum of 3 strategic referrals in the US) with 18-month expiry.

    Ian Meredith said:

    "I am delighted to join EYEFI's US advisory board to help drive/design/guide the expansion of this technology into the rapidly evolving healthcare milieu. As every step on the healthcare continuum continues its remarkable digital transformation in the 21st century, there may well be significant opportunities to integrate EYEFI's inspired technology into meaningful healthcare solutions. I am delighted to have the opportunity to help guide this translation."

    About EYEfi in detail:

    EYEfi is connecting the world's people and devices with the world around them, in real-time and in ways not previously possible.

    EYEfi is a software and electronics engineering company that has developed, patented and commercialized an innovative spatial technology; spatial, predictive, approximation and radial convolution (SPARC) and an associated product suite, that turns sensors, cameras and smartphones (fixed, mobile, airborne, portable or handheld) into geo-target co-ordinate acquisition devices.

    EYEfi has also developed IIoT sensor hardware and associated cloud software, as a second pillar within its product offering. EYEfi Cloud is a next generation cloud platform that provides a secure and centralized environment where customers can manage their EYEfi product deployments and applications.

    On behalf of the board of directors of
    EYEFI GROUP TECHNOLOGIES INC.

    "Simon Langdon"
    Simon Langdon, CEO

    For more information contact:

    Simon Langdon
    Chief Executive Officer
    EYEfi Group Technologies Inc.

    Mark van der Horst
    Investor Relations
    EYEfi Group Technologies Inc.
    Telephone: +1 (604) 760 7604
    Email: [email protected]

    THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

    FORWARD LOOKING INFORMATION

    This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information.

    The forward-looking statements are based on the reasonable assumptions, estimates, opinions and analyses of management made in light of its experience and perception of historical trends in the delivery of services through its Cloud, current conditions, expected future developments and other factors management of the Company believes are appropriate, relevant and reasonable in the circumstances at the date that such statements are made. All of these assumptions, estimates and opinions will necessarily be subject to change due to future events and other circumstances outside the control of the Company, including the effect of the Covid 19 virus. The Company has based the forward looking information on various material assumptions, including: despite the threat of the Covid 19 virus, the Company will sustain or increase profitability although on a slower projection then previously planned, and will be able to fund its operations with existing capital and projected revenue from its current agreements with its Channel Partners; the Company will be able to attract and retain key personnel in future if required; the general business, economic, financial market, regulatory and political conditions in which the Company operates will remain positive as its services can be provided in the Company's Cloud although deliver of its hardware may be affect by supply chain disruptions; that the general regulatory environment will not change in a manner adverse to the business of the Company; the tax treatment of the Company and its subsidiary will remain constant and the Company will not become subject to any material legal proceedings; the economy generally; competition, and anticipated and unanticipated costs.

    Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors, assumptions and exclusions is not exhaustive.

    The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

    SOURCE: EYEFI Group Technologies Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/652789/EYEFI-Expanding-to-the-United-States

    Get the next $BSX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BSX

    DatePrice TargetRatingAnalyst
    6/16/2025$118.00Outperform
    Leerink Partners
    4/16/2025$113.00Hold → Buy
    Needham
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    10/18/2024Buy → Hold
    Needham
    5/30/2024$90.00Buy
    Goldman
    2/1/2024$65.00 → $80.00Neutral → Buy
    Mizuho
    7/19/2023$59.00Outperform
    Robert W. Baird
    6/30/2023$64.00Buy
    CL King
    More analyst ratings

    $BSX
    SEC Filings

    See more
    • SEC Form 11-K filed by Boston Scientific Corporation

      11-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      6/18/25 5:14:10 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Corporation filed SEC Form 8-K: Other Events

      8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      5/28/25 7:45:47 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Boston Scientific Corporation

      SD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      5/22/25 4:10:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael exercised 56,372 shares at a strike of $26.15 and sold $5,799,630 worth of shares (56,372 units at $102.88) (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      6/4/25 7:44:50 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Chairman, President & CEO Mahoney Michael F exercised 105,619 shares at a strike of $20.67 and sold $17,051,136 worth of shares (164,443 units at $103.69), decreasing direct ownership by 4% to 1,476,882 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      6/3/25 4:47:04 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Director Ludwig Edward J sold $418,368 worth of shares (4,000 units at $104.59), decreasing direct ownership by 15% to 22,479 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      5/30/25 4:08:27 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Boston Scientific with a new price target

      Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

      6/16/25 7:46:14 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Needham with a new price target

      Needham upgraded Boston Scientific from Hold to Buy and set a new price target of $113.00

      4/16/25 9:01:10 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Boston Scientific from Hold to Buy and set a new price target of $108.00

      1/10/25 8:51:50 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces upcoming investor conference schedule

      MARLBOROUGH, Mass., May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in two upcoming investor conferences in May. On May 13, 2025, Dan Brennan, executive vice president and chief financial officer, and Joe Fitzgerald, executive vice president and group president, Cardiology, will participate in a 30-minute question-and-answer session with the host analyst at Bank of America's 2025 Health Care Conference. The session will begin at approximately 8:00 a.m. PT / 11:00 a.m. ET. On May 28, 2025, Mike Mahoney, chairman and chief executive officer,

      5/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan

      MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the company. Brennan will transition out of the chief financial officer position at the end of June and is expected to remain with Boston Scientific as a senior advisor through early October 2025.   "I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific," said Mike Mahoney, chairman and chief executi

      4/23/25 6:45:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      2/13/25 4:32:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 1, 2024 - FDA Roundup: March 1, 2024

      For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

      3/1/24 4:00:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    Leadership Updates

    Live Leadership Updates

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

      Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

      4/3/25 11:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

      BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

      1/6/25 9:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

      SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

      2/13/24 5:00:46 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

      SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

      2/9/24 11:49:03 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

      SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

      2/9/24 8:35:54 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific announces results for first quarter 2025

      MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.

      4/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing first quarter 2025 results

      MARLBOROUGH, Mass., April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 23 prior to the conference call. A live webcast and replay for the

      4/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces results for fourth quarter and full year 2024

      MARLBOROUGH, Mass., Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million or $0.38 per share (EPS), compared to $504 million or $0.34 per share a year ago and achieved adjusted3 EPS of $0.70 for the period, compared to $0.55 a year ago.

      2/5/25 6:37:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care